IN VIVO TESTING OF A LEAD COQ10 BIOSYNTHESIS INHIBITOR IN AN SK-BR-3 XENOGRAPH MOUSE MODEL

NCATS TDB一直在与哥伦比亚大学Brent Stockwell博士的团队合作，开发用于治疗癌症的辅酶q10生物合成的小分子抑制剂。目前，我们有一系列的抑制剂在体外表现出良好的效力和选择性。我们希望在移植了SK-BR-3人乳腺癌细胞的小鼠模型中测试我们的先导抑制剂。NCATS没有体内功效测试设施，也没有能力运行体内功效模型，因此必须通过承包商获得这项服务。

NCATS TDB has been collaborating with Dr Brent Stockwell’s group at Columbia Univ. to develop small molecules inhibitors of CoQ10 biosynthesis for the treatment of cancer. Currently, we have a series of inhibitors that show good potency and selectivity in vitro. We would like to test our lead inhibitor in a mouse model xenografted with SK-BR-3 human breast cancer cells. NCATS does not have in vivo efficacy testing facility nor capacity to run in vivo efficacy models, and therefore must get this service through a contractor.